U.S. FDA Accepts Merck's Gefapixant New Drug Application for Review
Search jobs U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review Application for Orally Administered Selective P2X3 Receptor Antagonist Based on Findings from Two Phase 3 Trials in Patients with Refractory or Unexplained Chronic Cough Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for gefapixant, an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refrac...
Source: pharmiweb.com